KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kura Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
-449.9%
Net margin
-412.9%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +25.2% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -39.7% | -21.6% | -94.8% | |
| Return on assets | -35.1% | -20.2% | -37.2% | |
| Current ratio | 12.62 | 24.49 | 6.06 | |
| Debt to equity | 0.13 | 0.01 | 0.06 | |
| Interest coverage | – | – | -200.8× | |
| Capex to revenue | – | – | 9.8% | |
| Diluted shares | 19M | 53M | 88M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Kura Oncology generated $537.81M from operations and spent $9.05M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$537.81M
Used
$9.05M
Capital expenditure$9.05M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-412.9%
×Asset turnover0.09×
×Equity multiplier2.55×
=Return on equity, FY2025-94.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -412.9% | 0.09× | 2.55× | -94.8% |
| FY2024 | -322.9% | 0.09× | 1.49× | -42.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$278.67M
- Cash generatingOperating cash flow above zero-$64.06M
- Return on assets improvedROA up on the prior year-38.8% → -36.7%
- Earnings backed by cashOperating cash flow above net income-$64.06M vs -$278.67M
- Less leverageLong-term debt to assets fell0.9% → 1.3%
- Better liquidityCurrent ratio rose9.46 → 6.06
- No dilutionShare count did not rise86M → 88M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.12 → 0.09